Patent Discovery Corp. (PDC) has acquired exclusive rights to Advanced Drug Delivery Emulsion (ADDE), a new drug delivery technology that should allow the intravenous (IV) administration of numerous macrolide drugs, including Clarithromycin and other broad-spectrum antimicrobials.
ADDE was originally developed by Latitude Pharmaceuticals Inc of San Diego, California and utilizes an emulsion process that should substantially reduce the myriad patient complaints associated with the IV administration of many macrolide drugs, including local tolerability (e.g., phlebitis, vein inflammation and vein irritation). These complications are so well defined that certain drugs, including Clarithromycin, are not currently approved for IV administration in the United States.
"ADDE is very appealing as new method to deliver broad-spectrum antibiotics due to the broadening of each drug's therapeutic index. We intend to identify suitable outlicensing partners to further develop and commercialize this novel technology," commented Robb McDaniels, PDC's President. Latitude's President and the inventor of ADDE, Dr. Andrew Chen, added, "The ADDE approach to macrolide therapies may well solve the issues that have prevented their broad availability for IV administration and will give physicians an additional weapon in their arsenal in fighting bacterial infections."